Menotrophin Ferring

Menotrophin, the active ingredient in Menotrophin Ferring, is a human menopausal gonadotropin (hMG) presented as an injectable solution for intramuscular or subcutaneous use. It provides exogenous FSH and LH activity to stimulate ovarian follicular development and ovulation in women with infertility.

GNH USA supplies Menotrophin Ferring as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Menotrophin is used in reproductive medicine to support follicular growth and ovulation. - Infertility due to anovulation: facilitates follicular development and induces ovulation in women who do not ovulate spontaneously. - Controlled ovarian hyperstimulation: enhances response to stimulation protocols for egg retrieval in assisted reproduction cycles. - Assisted reproductive technology (ART) procedures: provides necessary gonadotropin support during in‑vitro fertilisation (IVF) and related techniques.

Menotrophin may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Headache: transient headache of varying intensity. - Nausea: occasional nausea without vomiting. - Abdominal bloating: mild abdominal distension.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS): potentially severe fluid shift and ovarian enlargement. - Multiple pregnancy: increased risk of twins or higher‑order gestations. - Allergic reaction: rare anaphylaxis or hypersensitivity at the injection site.

Before prescribing Menotrophin, clinicians should consider the following precautions. - Patient selection: assess ovarian reserve and baseline hormone levels to tailor therapy. - Monitoring: perform regular ultrasound and estradiol measurements to detect excessive response. - Thromboembolic risk: evaluate history of clotting disorders as gonadotropin therapy may increase risk. - Pregnancy testing: confirm absence of pregnancy before initiating treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menotrophin can interact with other medications that affect ovarian response or hormone levels.

Major Interactions (Avoid): - GnRH agonists used for down‑regulation: may amplify ovarian response leading to OHSS. - Estrogen‑containing contraceptives: can blunt the intended gonadotropin effect.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased risk of ovarian cyst‑related bleeding. - Thyroid hormone therapy: altered metabolism may affect gonadotropin activity. - Corticosteroids: may modify ovarian response and require dose adjustment.